Impact of a 6-month treatment with intragastric balloon on body composition and psychopathological profile in obese individuals with metabolic syndrome.

Erika P Guedes,Maria Lucia F Farias,Miguel Madeira,Thiago T Mafort,Amélio F Godoy-Matos,Eduardo Madeira,Agnaldo J Lopes,Laura Maria C Mendonça,Rodrigo O Moreira

doi:10.1186/s13098-016-0197-6

Abstract

BackgroundThe aim of this study was to investigate the effects of a 6-month treatment with intragastric balloon (IGB) on body composition and depressive/anxiety symptoms in obese individuals with metabolic syndrome (MS).MethodsFifty patients (aged 18–50 years) with obesity and MS were selected for treatment with IGB for 6 months. Body composition was verified with dual-energy X-ray absorptiometry (DXA) at baseline and right after IGB removal. Anxiety/depressive symptoms were assessed with the Beck Depression Inventory (BDI) and the hospital anxiety and depression scale (HADS) at baseline and after 6 months of treatment.ResultsIn total, 39 patients completed the study. After 6 months, there were significant decreases in weight (11.7 ± 9.6 kg, p < 0.0001) and waist circumference (9.3 ± 8.2 cm, p < 0.0001). Weight loss was also demonstrated by DXA and corresponded to decreases of 3.0 ± 3.4% in body fat percentage, 7.53 ± 7.62 kg in total body fat, and 3.70 ± 4.89 kg in lean body mass (p < 0.001 for all comparisons). Depressive symptoms scores decreased by a mean of 4.57 ± 10.6 points when assessed with the BDI (p = 0.002) and 1.82 ± 5.16 points when assessed with the HADS-Depression (p = 0.0345). Anxiety symptoms scores decreased by a mean of 1.84 ± 4.04 points when determined with the HADS-anxiety (p = 0.0066). The decrease in body fat percentage was the parameter that best correlated with improvements in depressive (p = 0.008) and anxiety symptoms (p = 0.014).ConclusionsIn obese individuals with MS, fat mass reduction was associated with short-term improvements in depressive and anxiety symptoms. Trial Registration Registered at ClinicalTrials.gov, NCT01598233

Highlights

The aim of this study was to investigate the effects of a 6-month treatment with intragastric balloon (IGB) on body composition and depressive/anxiety symptoms in obese individuals with metabolic syndrome (MS)
Variations in body composition demonstrated by dual-energy X-ray absorptiometry (DXA) included a total body fat decrease of 7.53 ± 7.62 kg (p < 0.0001), corresponding to 3.0 ± 3.4% (p < 0.001), and a total lean mass decrease of 3.70 ± 4.89 kg (p < 0.001)
In addition to the weight loss already expected with IGB, significant improvements in depressive and anxiety symptoms were evidenced in this specific population

Summary

Introduction

The aim of this study was to investigate the effects of a 6-month treatment with intragastric balloon (IGB) on body composition and depressive/anxiety symptoms in obese individuals with metabolic syndrome (MS). Guedes et al Diabetol Metab Syndr (2016) 8:81 predictor of mental disorders, with a higher BMI showing a stronger association with depression [11]. Cugini et al analyzed the association between anxiety and depression with body composition, assessed with bioelectrical impedance These authors showed that anxiety and depression were influenced by relative reductions in lean mass and increase in fat mass in obese patients [13]. In a recent cross-sectional study, our group has shown that the percentage of total body fat—but not central fat, BMI, or waist circumference (WC)—was associated with an increased severity of anxiety and depressive symptoms in obese individuals with metabolic syndrome (MS) [15]

Objectives

Methods

Results

Discussion

Conclusion